In more than 70 countries, Biocon Biologics replaces Viatris in the biosimilars market.
In order to increase its presence in emerging markets, Biocon Biologics, a division of the large biopharmaceutical corporation Biocon, stated on Wednesday that it had successfully integrated the biosimilars business it had purchased from the American pharmaceutical company Viatris in more than 70 nations. The biosimilars division of Viatris was purchased by Biocon Biologics in November 2022. The merger will begin the process of transferring Viatris’ activities to Biocon Biologics on July 1, 2023. A biosimilar is a category of biological product that closely matches a reference biological product—also referred to as the originator or reference product—that has already received…